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Altered drug susceptibility during 
host adaptation of a Plasmodium 
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primate model
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Infections with Plasmodium falciparum, the most pathogenic of the Plasmodium species affecting man, 
have been reduced in part due to artemisinin-based combination therapies. However, artemisinin 
resistant parasites have recently emerged in South-East Asia. Novel intervention strategies are 
therefore urgently needed to maintain the current momentum for control and elimination of this 
disease. In the present study we characterize the phenotypic and genetic properties of the multi 
drug resistant (MDR) P. falciparum Thai C2A parasite strain in the non-human Aotus primate model, 
and across multiple passages. Aotus infections with C2A failed to clear upon oral artesunate and 
mefloquine treatment alone or in combination, and ex vivo drug assays demonstrated reduction in 
drug susceptibility profiles in later Aotus passages. Further analysis revealed mutations in the pfcrt and 
pfdhfr loci and increased parasite multiplication rate (PMR) across passages, despite elevated pfmdr1 
copy number. Altogether our experiments suggest alterations in parasite population structure and 
increased fitness during Aotus adaptation. We also present data of early treatment failures with an oral 
artemisinin combination therapy in a pre-artemisinin resistant P. falciparum Thai isolate in this animal 
model.
Antimalarial drug resistance is one of the greatest threats to the current malaria eradication agenda1. Oral 
artemisinin-based combination therapy (ACT) is the standard of care for uncomplicated malaria, while paren-
teral intravenous (i.v.) treatment is used in severe cases. Artemisinin (QHS) is the fast acting component of ACTs 
that accelerates clearing of young ring stage parasites by the spleen2. In 2009 decreased susceptibility to AS was 
first observed in western Cambodia3, and has since been detected in the rest of Southeast Asia, including recent 
reports of clinical treatment failure of ACTs such as artesunate/mefloquine (AS/MQ) or artemether/lumefan-
trine (AL or Coartem)4,5. In vitro selection experiments followed by genome-wide association studies have mean-
while identified mutations in the PF3D7_1343700 (PF13_0238) genomic locus encoding a Kelch protein that 
are strongly correlated with slow clearing parasites6. Such mutations appear to occur in the context of a specific 
genetic background in Southeast Asia but so far have not been detected in Africa7,8.
The TM90C2A (C2A) parasite is a multidrug resistant P. falciparum strain originally isolated from a patient in 
Thailand in 1992, prior to the observation of altered susceptibility to QHS in Southeast Asia9. Initial genotyping 
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demonstrated presence of quadruple-mutations in the dhfr-thymidylate synthase gene10 and increased pfmdr1 
copy number11. This combination of mutations and pfmdr1 copy number variation (CNV) has been associated in 
field isolates with higher in vitro inhibitory concentrations to MQ, quinine (QN), halofantrine and QHS, and with 
failure of MQ monotherapy and AS/MQ combination therapy at the Thai-Cambodian border12,13. Notably, AS/
MQ was deployed in 1994 in Thailand and adopted as standard treatment by the Thai health authorities in 2005. 
However, QHS monotherapy had been used in western Cambodia since the late 1970’s and MQ was introduced 
in Thailand in 19843.
Recently, we reported the adaptation of the Thai C2A clone to splenectomized Aotus l. lemurinus monkeys 
(Panamanian Owl monkey). Plasmodium infection in Aotus was first reported in Panama at the Gorgas Memorial 
Laboratory in 1966 and has since been established as a major non-human primate model to host-parasite-vector 
interactions, immunology and pathophysiology and evaluation of drugs and vaccines in P. falciparum and 
P. vivax14. During the adaptation process of passaging the parasite in Aotus, we observed decreasing susceptibil-
ity of the parasites to oral MQ or i.v. AS alone or in combination15. To determine the basis for the altered drug 
sensitivity phenotype during Aotus adaptation, we tested the antimalarial drug efficacy to MQ and artemisinin 
derivatives in vivo and in vitro in C2A, and correlated these parameters with growth rates, genotypic changes and 
mutations in antimalarial drug resistance genes.
Results
Artesunate treatment failure with the C2A P. falciparum strain in the Aotus model. We previ-
ously demonstrated treatment failures upon AS treatment with the multidrug resistant C2A in the Aotus monkey 
model15. Specifically, we observed recrudescence in monkey passage VII and suppression in passage VIII, in each 
case after treatment with AS at 20 mg/Kg i.v. for three days15. To systematically investigate this drug susceptibility 
phenotype we performed a controlled experiment in Aotus and followed parasitemia upon oral AS treatment 
alone, or in combination with MQ. Malaria naive and splenectomized male and female Aotus lemurinus lemuri-
nus monkeys were inoculated with 5 × 106 parasites of the C2A clone on its IX serial passage from a donor Aotus 
and further divided into three oral treatment groups of two monkeys each (Fig. 1, Table 1): one group was treated 
with a single dose of 40 mg/Kg of oral MQ; a second group was treated with daily doses of 33 mg/Kg of oral AS for 
three days; and a third group was treated with a combination of a single dose of oral MQ and three daily doses of 
oral AS. As a control a spleen intact animal was also infected and treated with the same dose regimen as the third 
group. Parasitemia was patent in all animals between days 1–2 post infection (PI), reaching peak parasitemia of 
> 100,000 parasites/μ L in groups 1–3 by day 9–11 PI. In contrast, a peak parasitemia of 340 parasites/μ L on day 
16 PI was reached in the spleen intact animal. On the first day > 100,000 parasites/μ L were reached treatment was 
initiated (Day 0 in Fig. 1).
In each of the three treatment regimes, the animals remained parasitemic with 10–100 parasites/μ L for > 10 
days (Fig. 1A, Table 1 and S3). In the spleen intact animal, parasitemia persisted at low levels until treatment 
on day 16 PI and was cleared by day 3 of treatment (Fig. 1B). In contrast, when splenectomized animals were 
infected with parasites from Aotus passages III and IV and treated i.v. with AS at 33 mg/Kg for 3 days and MQ at 
40 mg/Kg once at peak parasitemia (< 100,000 parasites/μ L), parasites were cleared on average on day 5 following 
initiation of treatment (Fig. 1C, Table S3). Similar clearance times are found in human cohorts: in one study 25% 
of patients with parasitemia >4% (> 100,000 parasites/μ L) were positive beyond day 3 of treatment, but only 5% 
with parasitemia <4%16. Notably, the i.v. AS dosage used in our study is about eight-fold higher than what is com-
monly given to humans for oral treatment of uncomplicated17,18 or severe malaria (33 mg/Kg versus 4 mg/kg)19. 
Converting the Aotus animal dose of AS used in this study (33 mg/Kg) to a human equivalent dose based on 
body surface area20 would result in ~11 mg/Kg, approximately three times the human standard dose of 4 mg/Kg. 
Together these experiments demonstrate that infections with the MDR C2A isolate in the Aotus/P. falciparum 
non-human primate model show characteristics of MQ resistance and reduced AS susceptibility, including par-
asite suppression upon i.v. or oral AS at 33 mg/Kg × three days, or in combination with MQ at 40 mg/Kg once 
(Fig. 1).
C2A shows altered drug susceptibility profiles ex vivo. To further investigate the drug resistance pro-
file of the C2A strain we performed ex vivo assays of C2A from several Aotus passages with a series of antimalarial 
compounds. Specifically, we determined the ex vivo IC50 values for Aotus passages II and X and the original 
in vitro-adapted TM90C2A isolate against MQ, CQ, atovaquone (ATV), QHA, DHA and AS (Fig. 2). As a control 
we also measured the IC50 of the sensitive D6 strain (CQ and MQ susceptible). These experiments confirmed 
that TM90C2A is indeed resistant to MQ, CQ and ATV (Fig. 2A), as observed in our previous experiments 
in the Aotus model15. MQ IC50s are > 30 nM, a concentration that has been associated with treatment failures 
in infected patients21,22. Interestingly we also observed reduced susceptibility with C2A to the three different 
artemisinin derivatives, QHA, DHA and AS, and compared to D6 (Fig. 2B). IC50 concentrations were above the 
previously defined thresholds of 12 nM21 for DHA (C2A passage X), and 20 nM21,23 for AS (C2A passages II and 
X). Interestingly, parasites showed a significant decrease in susceptibility against MQ, QHS and DHA between 
in vitro-adapted TM90C2A and C2A passages II and X. In contrast, CQ IC50 was not significantly different across 
C2A passages. To further evaluate possible reduction in artemisinin susceptibility across C2A passages, we per-
formed the recently established ring stage assay (RSA)24. This experiment indeed demonstrated some reduced 
susceptibility for ex vivo C2A passages II and X compared to the in vitro-adapted original TM90C2A isolate and 
the D6 control (Fig. 2C), although still below the defined threshold of 1% ring stage survival for resistance24. 
Altogether these data demonstrated phenotypic changes in C2A across Aotus passages such as altered suscep-
tibility to QHS, DHA, and MQ. Interestingly the in vitro-adapted TM90C2A did not show any signs of altered 
artemisinin susceptibility while being equally resistant to MQ and CQ compared to the Aotus passages.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:21216 | DOI: 10.1038/srep21216
Genetic analysis of C2A during Aotus passages and in vitro adaptation. To track possible changes 
in the genetic composition of C2A across Aotus passages and during in vitro adaptation we first analyzed copy 
number variation (CNV) of pfmdr1 (Fig. 2D). These experiments demonstrated variation in pfmdr1 copy number 
between 2 and 2.5 across all passages, and copy number of 2 in the in vitro-adapted line, suggesting presence of 
mixed genotypes across Aotus passages.
Given the pfmdr1 CNV data and the observed drug resistant profiles with C2A, we performed detailed genetic 
analysis of C2A across passages and with the in vitro-adapted TM90C2A. To determine whether C2A represented 
Figure 1. Antimalarial drug responses of Plasmodium falciparum C2A infected Aotus monkeys.  
(A) Parasitemia response plots of Aotus monkeys infected with the P. falciparum C2A clone passage X. Animals 
were inoculated with 5 × 106 infected red blood cells from a donor monkey (MN26006, passage IX) and treated 
when parasitemia reached > 105 parasites × μ L of blood. Panel (A) shows group 1 animals treated with MQ at 
40 mg/Kg orally once, group 2 animals treated with AS at 33 mg/Kg orally × three days and group 3 animals 
treated with MQ and AS at 33 mg/Kg × three days and MQ at 40 mg/Kg orally once. Panel (B) shows a spleen 
intact control treated with AS at 33 mg/Kg × three days + MQ at 40 mg/Kg orally once on day 16 of infection. 
Panel (C) shows parasitemia responses of MN24058 and MN26008 inoculated with PfC2A passages III and IV 
respectively and treated with AS at 33 mg/Kg × three days i.v. + MQ at 40 mg/Kg orally once.
Group ID
Aotus
Weight 
g.
Parasitemia Day 
of 
peak Group
Regimen 
mg/Kg Route
Treatment
Day of 
treatment
Day 
rescue
Results 
primarySex
Peak 
103 × μL
Duration 
days
1 26058 2 829 104.60 11 MQ 40 p.o. 1 11 14 Failed
1 26033 1 758 272.74 9 MQ 40 p.o. 1 9 5 Failed
2 22028 2 764 449.73 9 AS 33 p.o. 3 9 10 Failed
2 26045 1 789 110.58 11 AS 33 p.o. 3 11 8 Failed
3 26063 1 782 177.84 9 AS + MQ 33 + 40 p.o. 3 + 1 9 16 Failed
3 26025 2 785 106.02 10 AS + MQ 33 + 40 p.o. 3 + 1 10 None Failed
4 23042 λ 1 724 0.340 16 AS + MQ 33 + 40 p.o. 3 + 1 16 None Cured
Table 1.  Parasitological treatment responses of Aotus monkeys infected with a Plasmodium falciparum 
C2A clone. Male = 1; Female = 2. MQ = mefloquine; AS = artesunate. λ = spleen intact. p.o. = per os.
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Figure 2. Ex vivo/in vitro antimalarial drug susceptibility and Pfmdr1 copy number variation of PfC2A 
across Aotus passages. (A,B) IC50 antimalarial drug nM concentration bar plots of reference strains D6 (white 
bar), in vitro culture adapted TM90C2A (blue bar) and pfC2A Aotus adapted passage levels II (black bar) and 
X (red bar). Drug IC50 nM resistance threshold (black line). Mean ± sample SEM (see also Table S1). (C) DHA 
drug susceptibility based on RSA. Survival percentage = DHA treated parasites/DMSO treated parasites × 
100. Red bar represents survival of artemisinin resistant positive control strain KH001-029, D6 is included as 
negative reference strain. Significant survival threshold (black line) is set at 1% as in Witkowski et al.24.  
(D) Passage level pfmdr1 copy number fold change of a Plasmodium falciparum C2A clone during adaption 
to Aotus monkeys. P. falciparum strains with two pfmdr1 gene copies are considered resistant to MQ. 
Mean ± sample SEM. Dashed line indicates threshold for pfmdr1 CN level indicative of MQ resistance. Dotted 
line indicates threshold for pfmdr1 CN level indicative of MQ sensitivity. MQ = Mefloquine; CQ = Chloroquine; 
ATV = Atovaquone; AS = Artesunate; QHS = Artemisinin; DHA = Dihydroartemisinin. p = Mann-Whitney U 
significance t test unpaired samples. ***p < 0.005; **p < 0.05.
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a single genotype across passages, despite the observed pfmdr1 CNV, we performed genotyping using a molec-
ular barcode assay that assesses the parasite genotype based on a combination of 24 neutral loci across the 14 
P. falciparum chromosomes25. Genotyping by molecular barcode assay demonstrated that C2A parasites across all 
passages from TM90C2A to passage X show identical or very closely related major haplotypes (Fig. 3A). Genetic 
analysis of drug resistance loci revealed resistance mutations across all passages including a mutation in the 
in vitro-adapted TM90C2A within the pfcrt (M74I, N75E, N76T, A220S, N326S, I356T) and pfdhfr (N51I, C59R, 
I164L, S108N) loci (Fig. 3B). No mutations were found in the Kelch K13 locus across TM90C2A and passage II, III 
and X. However, compared to the 3D7 reference sequence we found a tandem asparagine insert (NN) after codon 
142 in the propeller domain in passages II, III and X as well as in the in vitro-adapted TM90C2A. This mutation 
has been observed in other parasites and is not related to an artemisinin resistance phenotype26. Interestingly spe-
cific mutations in pfmdr1 (Y184F), pfdhps (A437G, A581G) and pfATPase (L263A) were only found in passages 
II and III (Fig. 3B). Similarly distinct sets of mutations were found in the in vitro-adapted TM90C2A in pfdhfr 
(N51Y, C59M) and pfATPase (L263I, A623R, I431L, S769A/N), and these parasites also harbor unique mutations 
in pfcytb (Y268E, M270S). Given the molecular barcode data these observations suggest that the original C2A 
strain was a mixture of closely related parasite genotypes from which at least two were selected during subsequent 
Aotus passages (represented by passages II/III and passages IV-X, respectively) and another genotype was selected 
during in vitro adaptation (TM90C2A).
Serial passaging of C2A in Aotus selects for increased growth phenotype. As in other biological 
systems P. falciparum adaptation (in vitro and in animals) selects for the genotypes with maximal growth in the 
absence of any other selection (i.e., drug pressure)27–29. Increased growth rates typically result in decreased drug 
susceptibility profiles as demonstrated in the rodent malaria model30. We therefore wanted to quantify the altered 
parasite growth rates across Aotus passages, as a possible contributor to the observed changes in drug suscep-
tibility. We analyzed growth rates during Aotus adaptation based on the recorded parasitemia from each of the 
10 passage experiments (Fig. 4A), considering the time (Fig. 4B) and peak parasitemia (Fig. 4C). Specifically we 
estimated parasite multiplication rate (PMR, Fig. 4D) from the median of all increases in parasitemia at 48-hour 
intervals averaged across monkeys in the same passage. These data demonstrated that parasite growth increased 
significantly from a PMR just above 1 in passage I to PMR of above 7 in passage X. Interestingly increased growth 
rates were not linked to genomic deletions on chromosomes 2 and 9 (Fig. S1) that occur frequently during in vitro 
parasite adaptation31 and have been observed phenotypically in a splenectomized monkey model32.
Discussion
In a previous study we observed MQ and AS treatment failures with the Thai multi-drug resistant PfC2A in Aotus 
monkeys15. Here we systematically investigate the antimalarial drug responses of this isolate and its changes 
during host adaptation.
Artemisinin resistance in humans is defined as reduced parasite clearance rate or persistence of micro-
scopically detectable parasites on the third day of ACT therapy33. We observed suppression and persistence of 
Figure 3. Molecular barcode and antimalarial drug resistance loci across C2A passages. (A) Plasmodium 
falciparum barcode. (B) Drug resistance genotyping profiles. nd = not determined; λ = spleen intact.
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microscopically detectable parasites beyond the third day of oral AS alone or in combination with MQ, indicating 
resistance of the Aotus-adapted PfC2A isolate based on the above definition. The observed phenotype is unlikely 
due to limited AS and/or MQ bioavailability by the oral delivery route as our previous experiments in Aotus with 
the FVO P. falciparum strain have efficiently cleared parasites at day 4 when AS was administered i.v. or orally at 
8 mg/Kg for three days34. Similarly MQ treatment as a single dose of 20 mg/Kg cleared parasites on day 5 follow-
ing initiation of treatment in Aotus infected with FVO35. However, we cannot exclude that an inoculum effect36 
may have contributed to the observed relative lower efficiency of the oral route at high parasitemia densities 
(≥ 100 × 103/μ L) compared to the i.v. route at low parasitemia (< 1.0 × 103/μ L). Finally, splenectomy may have 
resulted in reduced efficiency of artemisinin-mediated parasite clearance as discussed previously35.
In vitro and ex vivo experiments demonstrated reduced DHA susceptibility at later Aotus passages, although 
remaining below the standard resistance threshold of 1% ring stage survival. Genotyping experiments demon-
strated presence of wild type Kelch K13 locus across all C2A passages, therefore ruling out involvement of this 
major resistance locus in the observed in vivo and in vitro or ex vivo drug susceptibility phenotypes. We also 
demonstrated treatment failure upon MQ treatment in Aotus and MQ drug resistant phenotype in vitro and 
ex vivo. Pfmdr1 copy number fluctuated between 2 to 2.5 during Aotus adaptation while MQ susceptibility 
decreased at later passages. These observations contrast with in vitro studies where pfmdr1 de-amplification 
results in increased MQ susceptibility. For example, in an artelinic acid (AL)-resistant line of P. falciparum 
(W2AL80) and clones originating from it, pfmdr1 de-amplification resulted in partial reversal of resistance to AL 
and increased susceptibility to MQ, even in the absence of drug pressure37,38.
It is possible that both, reduced artemisinin susceptibility and MQ resistance during Aotus adaptation are due 
to increased growth rates. For example, treatment of neurosyphilis with the zoonotic malaria parasite P. knowlesi 
was eventually abandoned due to increased virulence of this species after multiple passages in humans39. We 
modeled PfC2A growth rates during Aotus adaptation and indeed demonstrated a significant increase in parasite 
Figure 4. Plasmodium falciparum C2A growth across Aotus passages. (A) Parasitemia plots from individual 
monkeys (colored lines) with time of treatment (black dotted lines) across each passage. Parasitemia was 
followed for up to 100 days post inoculation and frequently fell below detectability (disappearance of colored 
lines). (B) Day of peak parasitemia trend. The day of peak parasitemia is the time since inoculation when peak 
parasitemia was achieved, averaged across monkeys for each passage. (C) Peak parasitemia trend. The value of 
peak parasitemia is the maximum parasitemia reached over the course of infection, averaged across monkeys 
for each passage. (D) Parasite multiplication rate (PMR). The PMR is the median of parasitemia increases across 
48-hr periods over the course of an infection, averaged across monkeys for each passage. The data is modeled 
with linear regression.
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multiplication rate from near 1 (passage I) to above 7 (passage X). It is therefore possible that the increased 
growth (i.e., parasite fitness) during serial passaging in Aotus resulted in altered drug susceptibility phenotypes. 
Similar observations have been made in the mouse malaria model, where increased fitness in P. chabaudi corre-
lated with reduced susceptibility to artemisinin30.
In conclusion, we present a comprehensive study on Aotus adaptation of the multidrug resistant P. falciparum 
C2A strain. Combined phenotypic and molecular analysis of parasites across Aotus passages demonstrates that 
host adaptation has co-selected for reduced drug susceptibility in this non-human primate model. Our data 
also suggest that this model may be used for the evaluation of anti-malarial drugs against the recently detected 
Artemisinin resistant strains emerging from South-East Asia.
Materials and Methods
Plasmodium falciparum parasite strains. The original P. falciparum TM90C2A strain and subsequent 
passages in Aotus (Fig. 5)15, as well as ex vivo cultures thereof, were used in this study. In addition, the Aotus 
adapted strain P. falciparum FVO34,40 and in vitro adapted strains, D6, D10, CS2 and W2mef, were used as control 
parasites for these studies.
Animals. Monkeys of the species Aotus l. lemurinus (Panamanian Owl monkey) Karyotype VIII & IX41 were 
used in this study. Animals were housed at Gorgas Memorial Institute of Health Studies (ICGES) in Panama, 
and cared and maintained as described42. Briefly, the animals were kept in stainless steel 4 unit quads cages 
(Lab Products Inc., Seaford, DE) with dimensions of 27 × 23.5 × 29.5 inches. Each cage was fitted with a 
3⁄4-inch-diameter PVC pipe perch placed across 2/3 of the length of the cage and a 6-inch-diameter × 14.5 
inches long PVC T pipe nest-box attached to the roof and back of the cage with cable zip ties. Cages were routinely 
cleaned and sterilized at 180° F at weekly intervals in a cage washing machine (Steris®, Erie, PA). During experi-
mental infections the animals did not receive analgesics.
The experimental protocol was approved by the ICGES Institutional Laboratory Animal Care and Use 
Committee (CIUCAL) in accordance with procedures described in the “Guide for the Care and Use of Laboratory 
Animals,” 1996; protocol approval number 2006/02. All experiments described herein were performed in accord-
ance with the approved guidelines.
Drug efficacy studies in Aotus monkeys. To determine drug efficacy using the commonly used delivery 
route in humans, MQ and AS were applied orally alone or in combination. Six splenectomized male and female 
laboratory bred Aotus weighing between 758–829 g and one spleen intact control were inoculated intravenously 
(i.v.) in the saphenous vein with 5 × 106 parasitized erythrocytes of the C2A strain from a donor monkey (pas-
sage IX). The animals were splenectomized ~30 days prior to inoculation as described43 (Fig. 5, Table 1). Parasite 
density was determined daily by Giemsa stained thick blood smears using the method described by Earle and 
Perez44, with 50 μL of blood obtained with a lancet prick from the marginal ear vein. When parasitemia reached 
~100,000 infected RBCs/μ L, animals were assigned to one of the three treatment arms (groups) by weight and sex 
and treated as shown in Table S3. Drug doses were calculated on a milligram (mg) base per kilogram (kg) of body 
weight basis45. Oral administration of drugs was by gastric intubation with a 14 French red rubber catheter, while 
for i.v. administration a 25g butterfly needle was used. Response to treatment was categorized as no effect, parasite 
suppression without clearance, parasite clearance and recrudescence, or parasite clearance and cure. The day of 
parasite clearance was defined as the first of three consecutive days in which the thick blood films were parasite 
negative. The day of recrudescence was defined as the first of 3 consecutive days of positive thick blood films after 
a period of clearance. Parasite suppression was defined as a transient decrease in parasite density post-treatment 
without clearance15. Animals were considered cured if no recrudescence was observed after parasite clearance and 
100 days of follow up with twice a week negative thick smears.
Figure 5. Genealogy of Plasmodium. falciparum C2A adaptation to Aotus lemurinus lemurinus monkeys. 
Blue highlighted squares indicate samples from which gDNA was extracted for genetic studies. Aotus monkey 
numbers in bold mark those that have been used in this study.
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Before initiation of treatment, citrated whole blood was collected from each animal, plasma removed, and 
cryopreserved with Glycerolyte® in liquid nitrogen and labeled passage level X for further in vitro IC50s deter-
mination, Ring Susceptibility Assay (RSA) and genotypic studies. Rescue treatment with MQ at 40mg/Kg orally 
once and AS at 20 mg/Kg i.v. for three days was triggered by any of the following: Hematocrit (HTO) below 50% 
of baseline, thrombocytopenia (< 50 × 103/μ L) or signs of depression or anorexia as determined by the attending 
veterinarian. Two animals were also included in this study as historical references representing infections with 
C2A passages III (MN24058) and IV (MN26008) shown in Fig. 5 and Table S1.
In vitro drug assays. In vitro IC50 values were obtained using the hypoxanthine incorporation assay46. IC50 
cutoff values indicative of resistance were adopted from the literature as follows: > 100 nM for CQ21–23,47, 30 nM 
for MQ21,22,47, 20 nM for AS21,23, and 12 nM for DHA21. Resistance cutoff points for QHS and ATV were not 
available from the literature. Ex vivo parasite passages were cultured for up to 8 serial passages in RPMI media 
containing 25% human AB + serum and 4% packed red blood cells. Thin smears were stained with Giemsa for 
morphological studies and detection of gametocytes. In vitro ring stage 0–3 hours survival assays (RSA) were 
carried out as described24 and the threshold for resistance was established at 1% survival.
Genetic analysis of parasite strains. Molecular barcode and drug resistance genotyping. Genomic DNA 
was obtained from blood samples using phenol extraction-ethanol precipitation protocol for purification and 
concentration of DNA as described48. DNA concentrations of the samples were measured using a NanoDrop® 
spectrophotometer ND1000. Extracted DNA was pre-amplified and genotyped across 24 genomic loci with both 
high-resolution melting (HRM) and TaqMan technologies (Life Technologies, Grand Island, NY) as previously 
described25,49. Samples were diluted 1:20 and 5 μ L of each pre-amplified product used for the molecular bar-
code. TaqMan barcoding assays were run on a ViiA system (Applied Biosystems) and genotypes called using the 
pre-installed analysis software. To confirm haplotypes and determine drug resistance genotypes of the C2A Aotus 
passages, we used a high resolution melting (HRM) analysis as described50.
Pfmdr1 copy number variation (CNV). To determine CNV in the pfmdr1 gene across C2A Aotus-adapted pas-
sages, gDNA was extracted and used in a qPCR assay, as described13. Pfmdr1 fold changes between C2A passage 
levels III-X and reference strain FVO were calculated as described51. Fold change results were rounded to the 
next significant integer for the purpose of determining copy number. Primer sequences are included in Table S2.
Gene sequencing. To determine single nucleotide polymorphisms (SNPs) in the K13 propeller domain, PCR 
sequencing was carried out. The full ORF of K13 was PCR amplified using Phusion HF DNA Polymerase kit and 
primers 1F and 1R. The resulting PCR product of ~2.2kb was purified by gel extraction (QIAquick Gel Extraction 
Kit, Qiagen) and sequenced at Genewiz using primers 1F, 2F, 3F, 1R, 2R and 3R. Primer sequences are included 
in Table S2.
Chromosomal deletions. To determine whether common genomic deletions in the subtelomeric regions of either 
chromosome 2 or 9 occurred during C2A passages in Aotus, several loci were analyzed by PCR. For this purpose 
genomic DNA was extracted using Qiagen™ DNA kit across P. falciparum C2A Aotus-adapted passages, as well 
as P. falciparum reference strains FVO, D10 and 3D7. PCR amplification of genes PF3D7_0201500 (PFB0075c) 
and PF3D7_0202000 (PFB0100c) on chromosome 2, as well as PF3D7_0935400 (PFI1710w), PF3D7_0936300 
(PFI1755c), PF3D7_0936800 (PFI1780w) on chromosome 9 were carried out in a BioRad™ PCR machine using 
the following amplification program: 95o Celsius (C) × 5 minutes, 95 °C × 30 minutes, 51.4 °C × 30 minutes, 
61.0 °C × 3 minutes for 35 cycles, plus 72 °C × 10 minutes. Amplicons were loaded onto a 1% agarose gel and sub-
jected to electrophoresis at 150 Volts for 30 minutes, stained with ethidium bromide and photo-documentation 
done with a UV light reader. Primer sequences are included in Table S2; primers for KAHRP (PFB0100c) ampli-
fication were published previously52.
Statistical analysis. Prism 5 Graph Pad® Software was used to plot and calculate the mean and standard 
error of the mean (SEM), and the JMP® Pro 10.0.0 statistical program (SAS Institute Inc, Middleton, MA) was 
used for the Mann-Whitney U significance test between unpaired IC50 values for TM90C2A and passage levels 
II and X. Matlab R2013a was used to plot parasitemia curves and calculate parasite multiplication rate (PMR). 
PMR is modeled via polynomial regression using the polynomial degree corresponding to the lowest Akaike 
Information Criteria.
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